Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
GLGalmed Pharmaceuticals Ltd. logo

Galmed Pharmaceuticals Ltd. (GLMD)

NASDAQ · Currency in USD
$4.63 ▲ +0.81 (+21.05%)
At close: Sep 9, 4:00 PM ET. Market closed.
$4.66 ▲ +0.03 (+0.65%)
After hours: Sep 9, 7:56 PM ET

Summary

Previous Close
$3.83
Open
$3.91
Day's Range
$3.82 – $4.63
52 Week Range
$3.29 – $13.20
Volume
301,155
Avg. Volume
78,979
Market Cap
$4.78M
Beta (5Y Monthly)
0.67
PE Ratio (TTM)
--
EPS (TTM)
-$11.91
Earnings Date
Nov 25, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Galmed Pharmaceuticals Ltd.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
6
CEO
Allen Baharaff

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.

Earnings

Next report: Wed, Nov 25, 2026
EPS estimate -$3.12
DateEst.Actual
Sep 2, 2026-$3.12-$2.86Beat
Jul 8, 2026-$3.04-$2.32Beat
Mar 31, 2026-$0.51-$0.92Miss
Nov 26, 2025-$4.32-$0.33Beat
Aug 28, 2025-$0.83-$0.63Beat
May 22, 2025-$0.89-$0.62Beat

Analyst view

Rating: Buy
Buy 63% · Hold 38% · Sell 0%

Get free alerts on GLMD and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.